Annexon Inc (ANNX) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03589W1027
Annexon, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol ANNX, focuses on discovering and developing therapies for autoimmune, neurodegenerative, and ophthalmic conditions.
The company's flagship product, ANX005, is a monoclonal antibody currently undergoing Phase II/III clinical trials for guillain-barré syndrome, with additional trials planned for conditions like warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis.
Annexon is also progressing with ANX009, in Phase Ib trials for lupus nephritis, and ANX007, undergoing Phase II trials for geographic atrophy. Further, the company is working on ANX105, a monoclonal antibody for neurodegenerative disorders, and ANX1502, an oral small molecule targeting specific autoimmune diseases.
Established in 2011 and headquartered in Brisbane, California, Annexon aims to address critical medical needs through innovative therapies. To learn more, visit their official website: https://www.annexonbio.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
ANNX Stock Overview
| Market Cap in USD | 474m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2020-07-24 |
ANNX Stock Ratings
| Growth 5y | -3.98 |
| Fundamental | -83.4 |
| Dividend | - |
| Rel. Performance vs Sector | -2.15 |
| Analysts | 4.63/5 |
| Fair Price Momentum | 4.96 USD |
| Fair Price DCF | - |
ANNX Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
ANNX Growth Ratios
| Growth 12m | -11.40% |
| Growth Correlation 12m | 20% |
| Growth Correlation 3m | 19% |
| CAGR 5y | -29.72% |
| Sharpe Ratio 12m | -0.14 |
| Alpha vs SP500 12m | -31.12 |
| Beta vs SP500 5y weekly | 0.77 |
| ValueRay RSI | 16.69 |
| Volatility GJR Garch 1y | 72.32% |
| Price / SMA 50 | -16.52% |
| Price / SMA 200 | 25.67% |
| Current Volume | 1430.7k |
| Average Volume 20d | 1544.6k |
External Links for ANNX Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 29, 2024, the stock is trading at USD 4.70 with a total of 1,430,749 shares traded.
Over the past week, the price has changed by +3.41%, over one month by -34.45%, over three months by +1.08% and over the past year by -11.40%.
According to ValueRays Forecast Model, ANNX Annexon Inc will be worth about 5.5 in April 2025. The stock is currently trading at 4.70. This means that the stock has a potential upside of +16.6%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 15.6 | 232 |
| Analysts Target Price | 15.6 | 232 |
| ValueRay Target Price | 5.5 | 16.6 |